Related references
Note: Only part of the references are listed.Cationic Arginine-Rich Peptides (CARPs): A Novel Class of Neuroprotective Agents With a Multimodal Mechanism of Action
Bruno P. Meloni et al.
FRONTIERS IN NEUROLOGY (2020)
The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease
Christoforos Hadjichrysanthou et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
2020 Alzheimer's disease facts and figures
[Anonymous]
ALZHEIMERS & DEMENTIA (2020)
A Oligomer Elimination Restores Cognition in Transgenic Alzheimer's Mice with Full-blown Pathology
Sarah Schemmert et al.
MOLECULAR NEUROBIOLOGY (2019)
Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2
Sarah Schemmert et al.
NEUROBIOLOGY OF DISEASE (2019)
Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers
Anne Elfgen et al.
SCIENTIFIC REPORTS (2019)
Homomeric and Heteromeric Aβ Species Exist in Human Brain and CSF Regardless of Alzheimer's Disease Status and Risk Genotype
Erica Lana et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2019)
Toward the Mode of Action of the Clinical Stage All-D-Enantiomeric Peptide RD2 on Aβ42 Aggregation
Tao Zhang et al.
ACS CHEMICAL NEUROSCIENCE (2019)
Role of Hydrophobicity and Charge of Amyloid-Beta Oligomer Eliminating D-Peptides in the Interaction with Amyloid-Beta Monomers
Tamar Ziehm et al.
ACS CHEMICAL NEUROSCIENCE (2018)
Diffusible, highly bioactive oligomers represent a critical minority of soluble A beta in Alzheimer's disease brain
Wei Hong et al.
ACTA NEUROPATHOLOGICA (2018)
Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-D-enantiomeric peptides developed for the treatment of Alzheimer's disease
Elena Schartmann et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
Advancements of the sFIDA method for oligomer-based diagnostics of neurodegenerative diseases
Andreas Kulawik et al.
FEBS LETTERS (2018)
Extreme disorder in an ultrahigh-affinity protein complex
Alessandro Borgia et al.
NATURE (2018)
Large Soluble Oligomers of Amyloid β-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate
Ting Yang et al.
JOURNAL OF NEUROSCIENCE (2017)
Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's Disease
Janine Kutzsche et al.
MOLECULES (2017)
The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology
Thomas van Groen et al.
SCIENTIFIC REPORTS (2017)
Analysis of anticoagulants for blood-based quantitation of amyloid β oligomers in the sFIDA assay
Kateryna Kravchenko et al.
BIOLOGICAL CHEMISTRY (2017)
Nanoparticle standards for immuno-based quantitation of α-synuclein oligomers in diagnostics of Parkinson's disease and other synucleinopathies
Yvonne Herrmann et al.
CLINICA CHIMICA ACTA (2017)
Pharmacokinetic Properties of a Novel D-Peptide Developed to be Therapeutically Active Against Toxic β-Amyloid Oligomers
Leonie H. E. Leithold et al.
PHARMACEUTICAL RESEARCH (2016)
Pharmacokinetic properties of tandem D-peptides designed for treatment of Alzheimer's disease
Leonie H. E. Leithold et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
Biofunctionalized Silica Nanoparticles: Standards in Amyloid-beta Oligomer-Based Diagnosis of Alzheimer's Disease
Maren Huelsemann et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
Complement and microglia mediate early synapse loss in Alzheimer mouse models
Soyon Hong et al.
SCIENCE (2016)
Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation
Paolo Arosio et al.
NATURE COMMUNICATIONS (2016)
The aqueous phase of Alzheimer's disease brain contains assemblies built from ∼4 and ∼7 kDa Aβ species
Jessica M. Mc Donald et al.
ALZHEIMERS & DEMENTIA (2015)
QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomers
Oleksandr Brener et al.
SCIENTIFIC REPORTS (2015)
Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer's disease
Dietmar Rudolf Thal et al.
ACTA NEUROPATHOLOGICA (2015)
Amyloid Aggregation Inhibitory Mechanism of Arginine-rich D-peptides
O. O. Olubiyi et al.
CURRENT MEDICINAL CHEMISTRY (2014)
Treatment with D3 Removes Amyloid Deposits, Reduces Inflammation, and Improves Cognition in Aged AβPP/PS1 Double Transgenic Mice
Thomas van Groen et al.
JOURNAL OF ALZHEIMERS DISEASE (2013)
The Amyloid-β Oligomer Count in Cerebrospinal Fluid is a Biomarker for Alzheimer's Disease
Lei Wang-Dietrich et al.
JOURNAL OF ALZHEIMERS DISEASE (2013)
High-molecular weight Aβ oligomers and protofibrils are the predominant Aβ species in the native soluble protein fraction of the AD brain
Ajeet Rijal Upadhaya et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2012)
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Iryna Benilova et al.
NATURE NEUROSCIENCE (2012)
Distribution and binding of 18F-labeled and 125I-labeled analogues of ACI-80, a prospective molecular imaging biomarker of disease: A whole hemisphere post mortem autoradiography study in human brains obtained from Alzheimer's disease patients
Balazs Gulyas et al.
NEUROCHEMISTRY INTERNATIONAL (2012)
Fluorine-18 labeling of three novel D-peptides by conjugation with N-succinimidyl-4-[18F]fluorobenzoate and preliminary examination by postmortem whole-hemisphere human brain autoradiography
Mahabuba Jahan et al.
NUCLEAR MEDICINE AND BIOLOGY (2012)
Large Aggregates Are the Major Soluble Ab Species in AD Brain Fractionated with Density Gradient Ultracentrifugation
Dag Sehlin et al.
PLOS ONE (2012)
Development of a Small D-Enantiomeric Alzheimer's Amyloid-β Binding Peptide Ligand for Future In Vivo Imaging Applications
Susanne Aileen Funke et al.
PLOS ONE (2012)
GFAP Isoforms in Adult Mouse Brain with a Focus on Neurogenic Astrocytes and Reactive Astrogliosis in Mouse Models of Alzheimer Disease
Willem Kamphuis et al.
PLOS ONE (2012)
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling et al.
ALZHEIMERS & DEMENTIA (2011)
Early onset amyloid lesions lead to severe neuritic abnormalities and local, but not global neuron loss in APPPS1 transgenic mice
Niels J. Rupp et al.
NEUROBIOLOGY OF AGING (2011)
Oral Treatment with the D-Enantiomeric Peptide D3 Improves the Pathology and Behavior of Alzheimer's Disease Transgenic Mice
Susanne Aileen Funke et al.
ACS CHEMICAL NEUROSCIENCE (2010)
Inhibitors of Class 1 Histone Deacetylases Reverse Contextual Memory Deficits in a Mouse Model of Alzheimer's Disease
Mark Kilgore et al.
NEUROPSYCHOPHARMACOLOGY (2010)
In vitro and in vivo Staining Characteristics of Small, Fluorescent, Aβ42-Binding D-Enantiomeric Peptides in Transgenic AD Mouse Models
Thomas van Groen et al.
CHEMMEDCHEM (2009)
α-secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits Aβ generation
Sebastian Jaeger et al.
JOURNAL OF NEUROCHEMISTRY (2009)
Mirror image phage display-a method to generate D-peptide ligands for use in diagnostic or therapeutical applications
Susanne Aileen Funke et al.
MOLECULAR BIOSYSTEMS (2009)
Reduction of Alzheimer's Disease Amyloid Plaque Load in Transgenic Mice by D3, a D-Enantiomeric Peptide Identified by Mirror Image Phage Display
Thomas van Groen et al.
CHEMMEDCHEM (2008)
Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice
R. Minkeviciene et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Counting of single prion particles bound to a capture-antibody surface (surface-FIDA)
Eva Birkmann et al.
VETERINARY MICROBIOLOGY (2007)
Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease
Monica Garcia-Alloza et al.
NEUROBIOLOGY OF DISEASE (2006)
Exploratory activity and spatial learning in 12-month-old APP695SWE/co+PS1/ΔE9 mice with amyloid plaques
R Lalonde et al.
NEUROSCIENCE LETTERS (2005)
Cerebral microvascular amyloid β protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid β precursor protein
J Miao et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo:: evidence for augmentation of a 42-specific γ secretase
JL Jankowsky et al.
HUMAN MOLECULAR GENETICS (2004)
An in vitro and in vivo study of early deficits in associative learning in transgenic mice that over-express a mutant form of human APP associated with Alzheimer's disease
E Domínguez-del-Toro et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2004)
Prevention of Alzheimer's disease-associated Aβ aggregation by rationally designed nonpeptidic β-sheet ligands
P Rzepecki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Early-onset and robust cerebral microvascular accumulation of amyloid β-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid β-protein precursor
J Davis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Mirror-image phage display: Aiming at the mirror
K Wiesehan et al.
CHEMBIOCHEM (2003)
Selection of D-Amino-Acid peptides that bind to Alzheimer's disease amyloid peptide Aβ1-42 by mirror image phage display
K Wiesehan et al.
CHEMBIOCHEM (2003)
Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo
DM Walsh et al.
NATURE (2002)
Co-expression of multiple transgenes in mouse CNS: a comparison of strategies
JL Jankowsky et al.
BIOMOLECULAR ENGINEERING (2001)
Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy
TJ Grabowski et al.
ANNALS OF NEUROLOGY (2001)
Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons
J Van Dorpe et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
